Discover
BCTX
BriaCell Therapeutics Corp.
3.47
2 x 2.51
2 x 4.16
bid
ask
+
0.23
7.10%
2 @ 04:00 PM
3.48 +0.01 (0.29%)
| Ytd | -51.20% | |
| 1y | -87.87% |
3.26
day range
3.50
2.60
52 week range
31.10
| Open | 3.27 | Prev Close | 3.24 | Low | 3.26 | High | 3.50 | Mkt Cap | 30.19M |
| Vol | 174.41K | Avg Vol | 200.29K | EPS | -0.84 | P/E | N/A | Forward P/E | -1.38 |
| Beta | 1.82 | Short Ratio | 0.77 | Inst. Own | 4.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 06-16 | 50-d Avg | 3.50 | 200-d Avg | 6.54 | 1yr Est | 15.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-12-16 | 2024-10 | -0.08 | -0.22 | -0.14 | -175.00% |
| 2024-10-28 | 2024-07 | -0.52 | N/A | N/A | N/A |
| 2024-10-28 | 2024-07 | -0.52 | -0.07 | 0.45 | 86.54% |
| 2024-06-14 | 2024-04 | -0.55 | N/A | N/A | N/A |
| 2024-06-14 | 2024-04 | -0.55 | 0.11 | 0.66 | 120.00% |
| 2024-03-18 | 2024-01 | -0.2 | -0.71 | -0.51 | -255.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-09-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-06-04 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-02-16 | Lustig (Marc) | 10% Security Holder of Issuer | 0.00 | Acquisition or disposition in the public market |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-03-30 | Lynwood Capital Management Inc. | 1.60M | 857.83K | 3.61% |
| 2024-09-29 | Vontobel Holding Limited | 80.00K | 42.95K | 0.18% |
| 2024-09-29 | HRT Financial LP | 74.29K | 39.88K | 0.17% |
| 2024-09-29 | Onyx Bridge Wealth Group, LLC | 50.00K | 26.84K | 0.11% |
| 2024-09-29 | Group One Trading, L.P. | 37.89K | 20.34K | 0.09% |
| 2024-09-29 | Summit Trail Advisors, LLC | 35.00K | 18.79K | 0.08% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 7.23K | 3.88K | 0.02% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2025-08-25 |
| 1 : 15 | 2025-01-29 |
| 1 : 300 | 2020-01-02 |
| 307 : 1000 | 2014-12-03 |